See more : BRB – Banco de Brasília S.A. (BSLI4.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Pacira BioSciences, Inc. (PCRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pacira BioSciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Aptech Limited (APTECHT.NS) Income Statement Analysis – Financial Results
- Guangdong Lyric Robot Automation Co., Ltd. (688499.SS) Income Statement Analysis – Financial Results
- STS Evermedia Corporation (SEVM) Income Statement Analysis – Financial Results
- International Research Corporation Public Company Limited (IRCP.BK) Income Statement Analysis – Financial Results
- Fisher & Paykel Healthcare Corporation Limited (FPH.NZ) Income Statement Analysis – Financial Results
Pacira BioSciences, Inc. (PCRX)
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.98M | 666.82M | 541.53M | 420.83M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M | 85.55M | 39.08M | 15.69M | 14.56M | 15.01M | 13.93M |
| Cost of Revenue | 184.67M | 199.30M | 140.26M | 117.33M | 106.71M | 86.85M | 87.92M | 110.10M | 71.84M | 77.44M | 54.77M | 32.14M | 16.74M | 12.28M | 12.30M | 17.46M |
| Gross Profit | 490.31M | 467.53M | 401.28M | 303.50M | 314.31M | 250.43M | 198.72M | 166.27M | 177.16M | 120.23M | 30.78M | 6.95M | -1.05M | 2.29M | 2.71M | -3.54M |
| Gross Profit Ratio | 72.64% | 70.11% | 74.10% | 72.12% | 74.65% | 74.25% | 69.33% | 60.16% | 71.15% | 60.82% | 35.98% | 17.77% | -6.69% | 15.70% | 18.03% | -25.41% |
| Research & Development | 76.26M | 84.80M | 55.55M | 59.42M | 72.12M | 55.69M | 57.29M | 45.68M | 28.66M | 18.73M | 21.56M | 9.94M | 14.87M | 18.63M | 26.23M | 33.21M |
| General & Administrative | 116.40M | 109.52M | 88.32M | 74.83M | 71.12M | 70.16M | 66.69M | 63.40M | 61.31M | 41.65M | 20.96M | 15.97M | 20.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 153.04M | 145.00M | 111.02M | 118.68M | 129.66M | 107.11M | 94.80M | 89.22M | 77.73M | 65.01M | 41.55M | 30.33M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 269.44M | 254.52M | 199.35M | 193.52M | 200.78M | 177.27M | 161.49M | 152.61M | 139.04M | 106.66M | 62.51M | 46.31M | 20.16M | 6.03M | 5.02M | 8.61M |
| Other Expenses | 56.94M | 57.29M | 13.55M | 7.87M | 5.70M | -888.00K | 167.00K | -82.00K | -165.00K | -159.00K | -47.00K | -111.00K | 3.02M | 6.03M | 5.02M | 8.61M |
| Operating Expenses | 402.63M | 396.60M | 268.44M | 260.80M | 278.60M | 232.95M | 218.78M | 198.29M | 167.71M | 125.39M | 84.07M | 56.24M | 35.03M | 24.66M | 31.25M | 41.83M |
| Cost & Expenses | 587.30M | 595.90M | 408.70M | 378.13M | 385.32M | 319.80M | 306.70M | 308.40M | 239.54M | 202.83M | 138.84M | 88.38M | 51.77M | 36.93M | 43.55M | 59.29M |
| Interest Income | 11.44M | 4.54M | 896.00K | 4.63M | 7.38M | 6.50M | 4.08M | 1.32M | 678.00K | 382.00K | 259.00K | 275.00K | 255.00K | 146.00K | 77.00K | 235.00K |
| Interest Expense | 20.31M | 39.98M | 31.75M | 25.67M | 23.63M | 21.95M | 18.05M | 7.06M | 7.73M | 8.28M | 7.25M | 1.81M | 4.78M | 4.89M | 3.60M | 3.49M |
| Depreciation & Amortization | 75.57M | 91.50M | 28.55M | 19.91M | 19.58M | 13.17M | 13.83M | 12.92M | 11.48M | 10.04M | 5.75M | 5.65M | 4.31M | 4.25M | 4.43M | 3.83M |
| EBITDA | 157.58M | 144.78M | 118.47M | 71.42M | 55.29M | 33.06M | -10.59M | -17.86M | 21.39M | 5.09M | -50.73M | -44.55M | -34.23M | -19.12M | -24.12M | -41.53M |
| EBITDA Ratio | 23.35% | 18.22% | 26.71% | 15.89% | 10.41% | 6.85% | -5.52% | -11.14% | 4.00% | -2.50% | -55.32% | -125.71% | -185.14% | -124.20% | -163.15% | -296.65% |
| Operating Income | 87.68M | 60.02M | 131.07M | 46.35M | 38.11M | 15.92M | -24.94M | -32.02M | 9.46M | -5.17M | -53.29M | -49.30M | -39.10M | -22.37M | -28.55M | -45.36M |
| Operating Income Ratio | 12.99% | 9.00% | 24.20% | 11.01% | 9.05% | 4.72% | -8.70% | -11.59% | 3.80% | -2.61% | -62.29% | -126.13% | -249.23% | -153.63% | -190.24% | -325.77% |
| Total Other Income/Expenses | -25.97M | -46.72M | -33.52M | -26.26M | -26.66M | -16.34M | -17.53M | -5.82M | -7.34M | -8.38M | -11.06M | -2.98M | -4.23M | -4.78M | -3.16M | 3.50M |
| Income Before Tax | 61.70M | 13.30M | 56.40M | 20.09M | -10.75M | -425.00K | -42.47M | -37.84M | 2.12M | -13.54M | -64.35M | -52.28M | -43.33M | -27.15M | -28.18M | -45.59M |
| Income Before Tax Ratio | 9.14% | 1.99% | 10.42% | 4.77% | -2.55% | -0.13% | -14.82% | -13.69% | 0.85% | -6.85% | -75.22% | -133.77% | -276.17% | -186.44% | -187.80% | -327.38% |
| Income Tax Expense | 19.75M | -2.61M | 14.42M | -125.43M | 268.00K | 46.00K | 140.00K | 105.00K | 264.00K | 173.00K | -442.00K | -3.95M | 7.25M | 4.78M | 3.16M | -3.50M |
| Net Income | 41.96M | 15.91M | 41.98M | 145.52M | -11.02M | -471.00K | -42.61M | -37.95M | 1.86M | -13.72M | -63.91M | -52.28M | -43.33M | -27.15M | -31.71M | -41.86M |
| Net Income Ratio | 6.22% | 2.39% | 7.75% | 34.58% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.70% | -133.77% | -276.17% | -186.44% | -211.30% | -300.62% |
| EPS | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EPS Diluted | 0.81 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| Weighted Avg Shares Out | 46.22M | 45.52M | 44.26M | 42.67M | 41.51M | 40.91M | 39.81M | 37.20M | 36.54M | 35.17M | 33.11M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
| Weighted Avg Shares Out (Dil) | 51.98M | 46.54M | 45.63M | 43.68M | 41.51M | 40.91M | 39.81M | 37.24M | 41.30M | 35.30M | 33.18M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under...
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PCRX
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024,...
PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024,...
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
PCRX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacira BioSciences, Inc.
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024,...
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 --
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pacira BioSciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PCRX
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024,...
ATTENTION Pacira BioSciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024,...
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's...
Source: https://incomestatements.info
Category: Stock Reports